Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 31510 [2023-10499]

Download as PDF 31510 Federal Register / Vol. 88, No. 95 / Wednesday, May 17, 2023 / Notices building, and preparedness and response capabilities by fostering a shared understanding of Sector risks, needs, and opportunities. SRMAs are expected to determine the extent to which their respective sectors are implementing infrastructure protection frameworks and guidance (e.g., cybersecurity). Per the 2013 National Infrastructure Protection Plan (NIPP), they ‘‘serve as a day-to-day Federal interface for the dynamic prioritization and coordination of sector-specific activities and carry out incident management responsibilities’’. CIP’s success as the SRMA depends heavily on routine and ad hoc data to inform its programs and activities in the HPH Sector. CIP plans to collect data bi-annually to understand the impact of the HPH Partnership’s work on HPH Sector resilience. Using survey-based data collection tools, CIP will measure the performance of the HPH Partnership as a program and use the resulting information to assess the Office’s responsiveness to its statutory responsibilities, including those articulated in Section 2009(b) in the 2021 NDAA. The data will additionally support CIP’s ability to improve programmatic operations and inform decision-making. CIP will also collect data under urgent circumstances to guide emergency response activities and after-action reporting for the HPH Sector. ANNUALIZED BURDEN HOUR TABLE HPH Partnership Bi-Annual Survey Collection (Fall). HPH Partnership Bi-Annual Survey Collection (Spring). Ad hoc Information Collections ................. HPH Partnership Members ...... 308 1 15/60 77 HPH Partnership Members ...... 308 1 15/60 77 HPH Partnership Members ...... 308 1 1 308 Total ................................................... .................................................. ........................ 3 ........................ 462 [FR Doc. 2023–10490 Filed 5–16–23; 8:45 am] BILLING CODE 4150–37–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Meeting of the Advisory Committee on Blood and Tissue Safety and Availability index.html when this information becomes available. FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS Policy, Office of the Assistant Secretary for Health, Department of Health and Human Services, Tower Building, 1101 Wootton Parkway, Rockville, MD 20852. Email: ACBTSA@hhs.gov. Phone: 202–795– 7608. On the day of the meeting, please go to https:// www.hhs.gov/live/ to view the meeting. The public will have an opportunity to present their views to the ACBTSA by submitting a written public comment. Comments should be pertinent to the meeting discussion. Persons who wish to provide written public comment should review instructions at https://www.hhs.gov/ oidp/advisory-committee/blood-tissuesafety-availability/meetings/2023-07-06/ index.html and respond by midnight June 28, 2023, ET. Written public comments will be accessible to the public on the ACBTSA web page prior to the meeting. Background and Authority: The ACBTSA is a discretionary Federal advisory committee and is governed by the provisions of the Federal Advisory Committee Act (FACA), Public Law 92– 463, as amended (5 U.S.C. app), which sets forth standards for the formation and use of advisory committees. The ACBTSA functions to provide advice to the Secretary through the Assistant SUPPLEMENTARY INFORMATION: Office of the Assistant Secretary for Health, Office of the Secretary, Department of Health and Human Services. AGENCY: ACTION: Notice. The U.S. Department of Health and Human Services is hereby giving notice that the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA) will hold a meeting. The meeting will be open to the public via webcast. The committee will discuss and vote on a recommendation related to surge capacity for blood and blood products. SUMMARY: The meeting will take place on July 6–7, 2023 from approximately 10 a.m.–3 p.m. Eastern Time (ET) each day. Meeting times are tentative and subject to change. The confirmed times and agenda items for the meeting will be posted on the ACBTSA web page at https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2023-07-06/ DATES: ddrumheller on DSK120RN23PROD with NOTICES1 Average burden per response Respondents (if necessary) Sherrette A. Funn, Paperwork Reduction Act Reports Clearance Officer, Office of the Secretary. Number of respondents Number of responses per respondents Forms (if necessary) VerDate Sep<11>2014 18:34 May 16, 2023 Jkt 259001 PO 00000 Frm 00033 Fmt 4703 Sfmt 9990 Total burden hours Secretary for Health on a range of policy issues to include: (1) Identification of public health issues through surveillance of blood and tissue safety issues with national survey and data tools; (2) identification of public health issues that affect availability of blood, blood products, and tissues; (3) broad public health, ethical, and legal issues related to the safety of blood, blood products, and tissues; (4) the impact of various economic factors (e.g., product cost and supply) on safety and availability of blood, blood products, and tissues; (5) risk communications related to blood transfusion and tissue transplantation; and (6) identification of infectious disease transmission issues for blood, organs, blood stem cells and tissues. The Committee has met regularly since its establishment in 1997. Dated: May 2, 2023. James J. Berger, Designated Federal Officer, Advisory Committee on Blood and Tissue Safety and Availability, Office of Infectious Disease and HIV/AIDS Policy. [FR Doc. 2023–10499 Filed 5–16–23; 8:45 am] BILLING CODE 4150–28–P E:\FR\FM\17MYN1.SGM 17MYN1

Agencies

[Federal Register Volume 88, Number 95 (Wednesday, May 17, 2023)]
[Notices]
[Page 31510]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10499]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Meeting of the Advisory Committee on Blood and Tissue Safety and 
Availability

AGENCY: Office of the Assistant Secretary for Health, Office of the 
Secretary, Department of Health and Human Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The U.S. Department of Health and Human Services is hereby 
giving notice that the Advisory Committee on Blood and Tissue Safety 
and Availability (ACBTSA) will hold a meeting. The meeting will be open 
to the public via webcast. The committee will discuss and vote on a 
recommendation related to surge capacity for blood and blood products.

DATES: The meeting will take place on July 6-7, 2023 from approximately 
10 a.m.-3 p.m. Eastern Time (ET) each day. Meeting times are tentative 
and subject to change. The confirmed times and agenda items for the 
meeting will be posted on the ACBTSA web page at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2023-07-06/ when this information becomes available.

FOR FURTHER INFORMATION CONTACT: James Berger, Designated Federal 
Officer for the ACBTSA; Office of Infectious Disease and HIV/AIDS 
Policy, Office of the Assistant Secretary for Health, Department of 
Health and Human Services, Tower Building, 1101 Wootton Parkway, 
Rockville, MD 20852. Email: [email protected]. Phone: 202-795-7608.

SUPPLEMENTARY INFORMATION: On the day of the meeting, please go to 
https://www.hhs.gov/live/ to view the meeting. The public 
will have an opportunity to present their views to the ACBTSA by 
submitting a written public comment. Comments should be pertinent to 
the meeting discussion. Persons who wish to provide written public 
comment should review instructions at https://www.hhs.gov/oidp/advisory-committee/blood-tissue-safety-availability/meetings/2023-07-06/ and respond by midnight June 28, 2023, ET. Written public 
comments will be accessible to the public on the ACBTSA web page prior 
to the meeting.
    Background and Authority: The ACBTSA is a discretionary Federal 
advisory committee and is governed by the provisions of the Federal 
Advisory Committee Act (FACA), Public Law 92-463, as amended (5 U.S.C. 
app), which sets forth standards for the formation and use of advisory 
committees. The ACBTSA functions to provide advice to the Secretary 
through the Assistant Secretary for Health on a range of policy issues 
to include: (1) Identification of public health issues through 
surveillance of blood and tissue safety issues with national survey and 
data tools; (2) identification of public health issues that affect 
availability of blood, blood products, and tissues; (3) broad public 
health, ethical, and legal issues related to the safety of blood, blood 
products, and tissues; (4) the impact of various economic factors 
(e.g., product cost and supply) on safety and availability of blood, 
blood products, and tissues; (5) risk communications related to blood 
transfusion and tissue transplantation; and (6) identification of 
infectious disease transmission issues for blood, organs, blood stem 
cells and tissues. The Committee has met regularly since its 
establishment in 1997.

    Dated: May 2, 2023.
James J. Berger,
Designated Federal Officer, Advisory Committee on Blood and Tissue 
Safety and Availability, Office of Infectious Disease and HIV/AIDS 
Policy.
[FR Doc. 2023-10499 Filed 5-16-23; 8:45 am]
BILLING CODE 4150-28-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.